Compare Abeona Therapeutics Inc (ABEO) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Summit Therapeutics Inc — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while Summit Therapeutics Inc trades at $15.78 (market cap $12.32B). The key difference: Summit Therapeutics Inc is far larger — about 33× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | SMMT | |
|---|---|---|
Market Cap | $373.32M | $12.32B |
Sector | Health | Health |
52-Week High | $7.23 | $29.32 |
52-Week Low | $4.17 | $13.05 |
Enterprise Value | $228.22M | $11.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Summit Therapeutics (SMMT) trades at $15.93, up 3.31% today, with a bullish technical signal despite mixed moving averages and overbought RSI readings. The company reported a net loss of -$1.08B in 2025 and negative ROE/ROA, but recent Phase III trial success for ivonescimab in lung cancer has driven optimism. Cash flow remains volatile, with 2025 net cash flow positive at $120.4M but turning negative in 2026 projections.
Outlook hinges on ivonescimab's regulatory approval and commercial potential, with a consensus price target of $22.93 implying 44% upside. High volatility and binary clinical outcomes pose significant risks, but strong analyst buy ratings (66.7%) reflect confidence in the drug's prospects. Investors face substantial dilution risk from a proposed $500M stock offering announced June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
